Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Rajat Sarkar, Suvankar Banerjee, Sk. Abdul Amin, et al.
European Journal of Medicinal Chemistry (2020) Vol. 192, pp. 112171-112171
Closed Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho, Alex H. Y. Chan, A. Ganesan
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12460-12484
Open Access | Times Cited: 574
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Bo Han, Xiang‐Hong He, Yanqing Liu, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 3, pp. 1522-1586
Closed Access | Times Cited: 322
HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya, Sk. Abdul Amin, Nilanjan Adhikari, et al.
Pharmacological Research (2020) Vol. 163, pp. 105274-105274
Closed Access | Times Cited: 187
A review: Pharmacological aspects of metal based 1,2,4-triazole derived Schiff bases
Wardha Zafar, Sajjad Hussain Sumrra, Zahid H. Chohan
European Journal of Medicinal Chemistry (2021) Vol. 222, pp. 113602-113602
Closed Access | Times Cited: 121
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 94
Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors
Goverdhan Lanka, Darakhshan Begum, Suvankar Banerjee, et al.
Computers in Biology and Medicine (2023) Vol. 166, pp. 107481-107481
Closed Access | Times Cited: 59
Pharmacological aspects of schiff base metal complexes: A critical review
Tuba Ashraf, Bakhat Ali, Hasnain Qayyum, et al.
Inorganic Chemistry Communications (2023) Vol. 150, pp. 110449-110449
Closed Access | Times Cited: 57
An assessment of crucial structural contributors of HDAC6 inhibitors through fragment-based non-linear pattern recognition and molecular dynamics simulation approaches
Suvankar Banerjee, Sandeep Jana, Tarun Jha, et al.
Computational Biology and Chemistry (2024) Vol. 110, pp. 108051-108051
Closed Access | Times Cited: 24
Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article
Nardin Wagih, Islam M. Abdel-Rahman, Nawal El‐Koussi, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 966-1010
Open Access | Times Cited: 2
Fight against novel coronavirus: A perspective of medicinal chemists
Sk. Abdul Amin, Tarun Jha
European Journal of Medicinal Chemistry (2020) Vol. 201, pp. 112559-112559
Open Access | Times Cited: 74
A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents
Kashif Haider, Mohd Shafeeque, Shaikh Yahya, et al.
European Journal of Medicinal Chemistry Reports (2022) Vol. 5, pp. 100042-100042
Open Access | Times Cited: 48
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer
Sravani Pulya, Ambati Himaja, Milan Paul, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12033-12058
Closed Access | Times Cited: 30
The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases
Ruyuan He, Bohao Liu, Boxin Geng, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 29
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
Antonio Curcio, Roberta Rocca, Stefano Alcaro, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 620-620
Open Access | Times Cited: 15
Arresting the bad seed: HDAC3 regulates proliferation of different microglia after ischemic stroke
Yue Zhang, Jiaying Li, Yongfang Zhao, et al.
Science Advances (2024) Vol. 10, Iss. 10
Open Access | Times Cited: 14
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator
Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
Medical Oncology (2024) Vol. 41, Iss. 4
Closed Access | Times Cited: 12
Stack-HDAC3i: A high-precision identification of HDAC3 inhibitors by exploiting a stacked ensemble-learning framework
Watshara Shoombuatong, Ittipat Meewan, Lawankorn Mookdarsanit, et al.
Methods (2024) Vol. 230, pp. 147-157
Closed Access | Times Cited: 9
HDAC3-Mediated Deacetylation of p21 Stabilizes Protein Levels and Promotes 5-FU Resistance in Colorectal Cancer Cells
Weilin Jin, J. Wang, Yang Feng, et al.
Advances in Cancer Biology - Metastasis (2025), pp. 100136-100136
Open Access | Times Cited: 1
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
Nilanjan Adhikari, Tarun Jha, Balaram Ghosh
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8827-8869
Closed Access | Times Cited: 46
Epigenetic Regulation: A Link between Inflammation and Carcinogenesis
Bianca Vezzani, Marianna Carinci, Maurizio Previati, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1221-1221
Open Access | Times Cited: 31
The role of protein acetylation in carcinogenesis and targeted drug discovery
Jingru Yang, Cong Song, Xianquan Zhan
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 29
HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
Lili Li, Shumin Hao, Meiling Gao, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 5, pp. 657-673
Open Access | Times Cited: 22
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group
Jian Liu, Younong Yu, Joseph Kelly, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 12, pp. 2476-2483
Open Access | Times Cited: 43
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Yuxiang Luo, Huilin Li
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8828-8828
Open Access | Times Cited: 40
KDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progression
Haoran Wei, Wenhao Ma, Xiaofei Lü, et al.
Cancer Communications (2021) Vol. 41, Iss. 9, pp. 904-920
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top